Australians living with type 1 diabetes will soon have access to Abbott Diabetes Care’s FreeStyle Libre 3 Plus continuous ...

ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.

Update: From 10, Diabetes Australia revised its ‘Fluffy White Bread’ advert to remove certain manufacturing references while maintaining its classification as an ultra-processed food (UPF).

PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite ...

Overblown fears surrounding GLP-1 weight loss drugs were already pressuring the stock when an onboarding stumble triggered a sell-off.

Adults with type 1 diabetes who continued or transitioned to the Omnipod 5 Automated Insulin Delivery (AID) System maintained ...

The FDA has cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in ...

The FDA has cleared Beta Bionics Inc.’s Mint, a new type of insulin patch pump.

Abbott's Libre Duo 10 Day tracks glucose and ketones in one FDA-authorized wearable. See how it works, who can use it, and ...

Waterloo-based SugarTrack Consulting combines real-time glucose monitoring with analysis and personalized guidance from a ...

Key opportunities include rapid point-of-care and home diagnostics, wearable chronic disease monitoring, graphene-enabled precision detection, neurobiosensors, digital health integration, ...

People with diabetes can now get an early warning when a dangerous complication starts to build in their bodies. The U.S. Food and Drug Administration (FDA) on Tuesday authorized the first wearable ...